Physician profile

Fred K Branditz

Pulmonary Disease · Zanesville, OH

NPI 1558347005

$338.22

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$22.09

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $79.86 2019-2024 Shingrix
Genentech USA, INC. $56.49 2019
Boehringer Ingelheim Pharmaceuticals, INC. $49.27 2019-2020
Insmed, INC. $33.17 2019
Astrazeneca Pharmaceuticals LP $32.37 2020
Ethicon INC. $25.19 2019
Novartis Pharmaceuticals Corporation $22.36 2020
Electromed, INC. $15.40 2019
Bayer Healthcare Pharmaceuticals INC. $12.50 2019
Actelion Pharmaceuticals US, INC. $11.61 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Fred K Branditz

$338.22

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/70167/fred-k-branditz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.